In a case that highlights the intersection of diabetes management technology and software patent enforcement, Display Technologies, LLC filed suit against Roche Diabetes Care, Ltd. in the Eastern District of Texas on December 11, 2023, asserting infringement of U.S. Patent Nos. US8671195B2 and US9300723B2. The accused product — Roche’s ACCU-CHEK Guide Me meter paired with the mySugr app — sits at the heart of Roche’s connected diabetes care ecosystem. After approximately 240 days of litigation, the parties filed a Joint Stipulation of Dismissal, and on August 7, 2024, the court dismissed all claims with prejudice, with each party bearing its own costs.

This case is significant for IP strategists and in-house counsel operating in the digital health and connected medical device space. Display Technologies, a non-practicing entity represented by Garteiser Honea PLLC, targeted a high-profile FDA-regulated consumer medical product — a pattern that signals continued NPE pressure on IoT-enabled health devices. R&D teams developing Bluetooth-paired diagnostic devices and companion apps should treat this outcome as a prompt to audit freedom-to-operate risk across display and data-communication patent families.

Case Overview

The Parties

The Patents at Issue

US8671195B2 and US9300723B2 relate to systems and methods for displaying and communicating data across networked or paired devices — broadly covering how information is transmitted, rendered, and managed between connected endpoint devices and companion software interfaces. In practical application, these patents appear directed at the kind of data communication and display architecture used when a hardware device like a glucose meter wirelessly syncs readings to a mobile application. Their claims are broad enough to implicate a wide range of connected medical and consumer electronics products that pair physical sensors with smartphone apps.

• • US8671195B2
• • US9300723B2

Legal Representation

Plaintiff Counsel: Garteiser Honea PLLC (lead: Randall T. Garteiser)
Defendant Counsel: Fish & Richardson LLP; Fish & Richardson PC (Dallas) (lead: Aaron P Pirouznia)

Litigation Timeline & Procedural History

The Eastern District of Texas, and specifically its Marshall Division, is one of the most plaintiff-friendly venues in U.S. patent litigation, known for its experienced patent docket, predictable scheduling orders, and historically high plaintiff win rates at trial. Filing in this district is a deliberate strategic choice by patent assertion entities seeking maximum settlement leverage. This was a first-instance district court case, meaning no appeal had been taken and the matter was resolved entirely at the trial level before any substantive rulings on invalidity or infringement were publicly issued.

The case lasted approximately 240 days — less than eight months — which is notably short for patent litigation in federal district court, where cases routinely extend two to three years through claim construction, summary judgment, and trial. The rapid resolution via Joint Stipulation of Dismissal with prejudice strongly indicates the parties reached a private settlement agreement. The stipulation explicitly noted that ‘the above-captioned case has been resolved,’ and the court dismissed all claims with prejudice with each side bearing its own costs — a standard settlement-driven dismissal structure that forecloses any future refiling on the same patents and accused products.

The Verdict & Legal Analysis

Outcome

The court accepted the parties’ Joint Stipulation of Dismissal and dismissed all claims and causes of action with prejudice on August 7, 2024. No damages award was publicly entered, no injunction was issued, and no claim construction ruling was published, as the case resolved before any substantive merits adjudication. Each party was ordered to bear its own costs, expenses, and attorneys’ fees, and all pending relief requests not explicitly granted were denied as moot.

Verdict Cause Analysis

The dismissal with prejudice following a joint stipulation reflects the following key procedural and strategic dynamics:

• The parties voluntarily agreed to resolve the dispute and jointly moved for dismissal, meaning no court found infringement or non-infringement — the merits were never adjudicated.
• Dismissal with prejudice bars Display Technologies from refiling the same claims against Roche on US8671195B2 and US9300723B2 with respect to the accused ACCU-CHEK Guide Me and mySugr products.
• The mutual cost-bearing arrangement is consistent with a negotiated settlement, as prevailing parties in contested litigation typically seek fee awards or cost shifting under 35 U.S.C. § 285.
• No Markman hearing or claim construction order was issued, so the scope of the asserted patents remains undefined by this proceeding, preserving enforcement optionality against other defendants.

Legal Significance

1. 1. Because no claim construction ruling was entered, the patents US8671195B2 and US9300723B2 carry no adverse judicial interpretation from this case, meaning Display Technologies retains the ability to assert them against other defendants in the connected medical device and consumer electronics space without a limiting construction on record.
2. 2. The rapid 240-day resolution underscores the Eastern District of Texas’s effectiveness as a settlement-pressure venue — defendants in resource-intensive regulated industries like medical devices often find early settlement economically preferable to prolonged litigation, even where invalidity defenses may be strong.
3. 3. The case contributes to a broader pattern of NPE assertions targeting companion app and IoT-paired device architectures, signaling that patent holders are increasingly scrutinizing the communication and display layers of connected health products rather than the underlying diagnostic technology itself.

Strategic Takeaways

For Patent Attorneys:

• When representing connected-device defendants against NPE assertions in the Eastern District of Texas, early IPR or ex parte reexamination filings at the USPTO can provide settlement leverage and potential stay of district court proceedings — particularly for aging patent families like these pre-2015 data communication patents.
• The mutual cost-bearing dismissal language is a tell for settlement; when drafting defense strategy budgets, account for the high probability of pre-Markman resolution in EDTX NPE cases and calibrate discovery investment accordingly.
• Attorneys prosecuting patents in the display and data communication space should study the claim language of US8671195B2 and US9300723B2 to identify claim differentiation opportunities and avoid prosecution history estoppel that could limit future enforcement against evolving IoT health architectures.
• For plaintiff-side NPE work, this case demonstrates that filing against premium branded medical device products with consumer-facing app ecosystems can generate efficient pre-trial resolutions, as defendants in regulated industries have heightened reputational and operational incentives to settle quickly.

For IP Professionals:

• In-house IP teams at connected medical device companies should conduct a landscape analysis of Display Technologies’ full patent portfolio to assess exposure across other products in their lineup — NPEs that settle one case frequently assert related patents against additional products or subsidiaries.
• Consider implementing a patent watch on continuation applications stemming from US8671195B2 (App. No. 11/999570) and US9300723B2 (App. No. 13/494097), as continuation claims may be drafted to more precisely target evolving connected health product architectures and re-trigger assertion risk.

For R&D Teams:

• Engineering teams building Bluetooth Low Energy or Wi-Fi paired diagnostic devices with companion mobile apps should proactively document design choices and seek FTO opinions covering data display and transmission patent families before product launch, as this case illustrates that the communication and display layers — not just core sensor technology — attract patent assertions.
• Design-around strategies for products in this space should focus on alternative data synchronization architectures (e.g., cloud-mediated rather than direct device-to-app communication) and UI rendering approaches that differentiate from the claim language of broad display-communication patents like those asserted here.